Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Kemwell Biopharma Acquires Cirrus Pharmaceuticals Inc.



Kemwell Biopharma, a global bio/pharmaceutical contract services company headquartered in Bangalore, India, announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C., USA.

Since its inception in 1997, Cirrus has developed expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms. It also offers stand-alone analytical services including stability studies.

Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company, said Anurag Bagaria, chairman and MD of Kemwell in a press statement. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA, and PMDA approved facilities in India and Sweden.”

Source: Kemwell Biopharma

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here